Jump to main content
Jump to site search

Issue 40, 2016
Previous Article Next Article

New synthetic approaches towards analogues of bedaquiline

Author affiliations

Abstract

Multi-drug resistant tuberculosis (MDR-TB) is of growing global concern and threatens to undermine increasing efforts to control the worldwide spread of tuberculosis (TB). Bedaquiline has recently emerged as a new drug developed to specifically treat MDR-TB. Despite being highly effective as a result of its unique mode of action, bedaquiline has been associated with significant toxicities and as such, safety concerns are limiting its clinical use. In order to access pharmaceutical agents that exhibit an improved safety profile for the treatment of MDR-TB, new synthetic pathways to facilitate the preparation of bedaquiline and analogues thereof have been discovered.

Graphical abstract: New synthetic approaches towards analogues of bedaquiline

Back to tab navigation

Supplementary files

Article information


Submitted
29 Aug 2016
Accepted
13 Sep 2016
First published
13 Sep 2016

Org. Biomol. Chem., 2016,14, 9622-9628
Article type
Paper

New synthetic approaches towards analogues of bedaquiline

D. L. Priebbenow, L. Barbaro and J. B. Baell, Org. Biomol. Chem., 2016, 14, 9622
DOI: 10.1039/C6OB01893A

Social activity

Search articles by author

Spotlight

Advertisements